Prostate cancer is one of the most common cancers among men. Many cases grow slowly and may never become life-threatening. Because of this, doctors often recommend a management approach called “active ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

A gene called FOXJ1 may drive resistance to taxane chemotherapy during treatment for advanced prostate cancer, according to a new study led by investigators at Weill Cornell Medicine and Beth Israel ...

Though high rates of the disease persist among the nearby Indigenous communities, the Canadian government is weighing rules that may allow energy giants to release treated mining waste into the river ...

J&J JNJ announced that the European Commission has approved its precision therapy, Akeega (niraparib and abiraterone acetate dual action tablet), for expanded use in prostate cancer. The regulatory ...

The FDA approved this combination tablet in the same population late last year based on the AMPLITUDE study data.

Roquefort Therapeutics is acquiring exclusive worldwide rights to a clinical-stage tumour inhibitor for £32m in an all-paper deal and raising £8.5 million.

Prostate cancer is one of the most common cancers affecting men around the world. In many countries, including Germany, it is the most frequently diagnosed cancer in men. Each year, about 65,000 men ...

Former President Joe Biden made a rare public appearance at the Friday, March 6, funeral for Jesse Jackson amid his cancer battle. Biden, 83, attended the ceremony for the civil rights activist — who ...

Researchers found men who ejaculated more often had fewer prostate cancer diagnoses, pointing to a possible biological ...

Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

Dr Fred Saad of the University of Montreal discusses the future direction of alpha emitter agents in the treatment of prostate cancer, emphasizing the logical progression of resea ...